Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AtriCureATRC -0.52%78 EV-to-EBIT is 663.68 as of Jul. 20, 2026. GuruFocus rates ATRC with a GF Score™ of 78/100 and a GF Value™ of $40.00 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 465 Medical Devices & Instruments companies, AtriCure ranks worse than 99.35% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
AtriCure's Enterprise Value for the quarter that ended in Mar. 2026 was $1,373.4 Mil.
AtriCure's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AtriCure EV-to-EBIT Related Terms
AtriCure EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for AtriCure's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, AtriCure's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AtriCure EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where AtriCure's EV-to-EBIT falls into.
AtriCure's current Enterprise Value is $1,686.4 Mil.
AtriCure's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AtriCure (ATRC) has a EV-to-EBIT of 663.68 as of Jul. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AtriCure and its competitors. According to the industry distribution chart, AtriCure ranks #462 out of 465 companies in the Medical Devices & Instruments industry, placing it in the top 99.4%.
Is AtriCure's EV-to-EBIT too high?
AtriCure's current EV-to-EBIT is 663.68. The Medical Devices & Instruments industry median EV-to-EBIT is 18.37. AtriCure's value of 663.68 is 3512.8% above this industry median. Based on the distribution chart, AtriCure ranks #462 out of 465 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, AtriCure has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AtriCure's EV-to-EBIT compare to KMTS and STAA?
According to the Medical Devices & Instruments industry distribution chart, AtriCure ranks #462 out of 465 companies for EV-to-EBIT. This places AtriCure in the lower half of its industry. The industry median EV-to-EBIT is 18.37. AtriCure's value of 663.68 is 3512.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.37, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AtriCure's current EV-to-EBIT of 663.68 is 3512.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AtriCure and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AtriCure's current EV-to-EBIT is 663.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtriCure stock overvalued right now?
Based on GuruFocus' analysis, AtriCure (ATRC) is currently considered Modestly Undervalued. The stock's GF Value™ is $40.00, compared to a current price of $34.77 — trading 13.1% below its estimated fair value. The current EV-to-EBIT is 663.68 and 3512.8% above the Medical Devices & Instruments industry median of 18.37. AtriCure's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For AtriCure (ATRC), the current EV-to-EBIT is 663.68 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AtriCure (ATRC) Overvalued in 2026?
Based on GuruFocus' analysis, AtriCure stock appears to be undervalued.
The current stock price of $34.77 is trading 13.1% below its estimated GF Value™ of $40.00.
GuruFocus considers AtriCure to be Modestly Undervalued.
Key valuation signals for ATRC:
EV-to-EBIT: 663.68
GF Value™: $40.00 vs. price of $34.77 (13.1% below fair value)
Industry Position: 3512.8% above the Medical Devices & Instruments median (#462 of 465)
No single metric tells the full story. See the ATRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
78GF Score
Get the complete analysis for ATRC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATRC has been successfully added to your 
